Roivant Shares Jump 17% as Lung Disease Drug Meets Trial Goals

3-line summary

• Roivant shares jumped 17% as its lung disease drug met trial goals, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.